EU to get 107 million COVID doses by end of March, 30 million from AstraZeneca
Reuters
Published Mar 31, 2021 07:20AM ET
BRUSSELS (Reuters) - European Union states are expected to receive 107 million doses of COVID-19 vaccines by the end of March, an EU Commission spokeswoman said on Wednesday, hitting an earlier target but far below initial plans.
Under contracts signed with drugmakers, the bloc had expected to receive 120 million doses by the end of March from Anglo-Swedish firm AstraZeneca (NASDAQ:AZN) alone and tens of millions more doses from Pfizer-BioNTech and Moderna (NASDAQ:MRNA).
But after major cuts from AstraZeneca, the EU had revised down its target until the end of March to about 100 million doses.
The Commission spokeswoman told a news conference that AstraZeneca was expected to deliver 29.8 million doses by Wednesday, in line with its revised-down goal.
Pfizer-BioNTech will deliver 67.5 million doses and Moderna nearly 10 million, figures that the EU has said are in line with their initial commitments.
The EU expects a major ramp-up of deliveries in the second quarter that it says will be sufficient to inoculate at least 70% of its adult population by July, and speed up its so far slow vaccination drive.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.